In the inaugural episode of Captivating Health Insights, host Maddison Bezdicek explored the promise and pitfalls of one of the most talked-about topics in healthcare: GLP-1 medications. Joined by Brenda Navin, CEO and Founder of Launch My Health, and Kelly Rawlings of Vida Health, the episode examined how GLP-1s, such as semaglutide and tripeptide, are reshaping the treatment of obesity and related metabolic conditions, and why lifestyle support and personalized care are key to lasting results.
The conversation began by explaining how GLP-1s work: they’re hormones that help suppress appetite and slow digestion, making it easier for patients to manage weight. However, as Navin emphasized, “There is no magic bullet.” Patients may face muscle loss, weight regain, and other long-term health risks without addressing nutrition, movement, and emotional well-being.
Rawlings shared how Vida Health incorporates GLP-1s into a broader care model, including cognitive behavioral therapy, nutritional support, and personalized coaching. This approach ensures patients lose weight and gain the tools to keep it off.
They also discussed the challenges of access and sustainability. With high costs and a surprising drop-off rate—up to 85% of patients discontinue use within two years—it’s clear that ongoing education and support are essential for long-term success.
Employers are increasingly at the center of this conversation. With employee demand rising, Navin and Rawlings explored benefit design strategies like centers of excellence and step therapy programs that support outcomes and cost control.
Key takeaway: GLP-1s are a promising tool in the fight against obesity, but they work best when combined with multidisciplinary care. Listen and subscribe on your favorite platforms, including YouTube, Apple, Spotify, Amazon Music, iHeartRadio, Pandora, and Pocket Casts to learn more about GLP-1s and how healthcare providers and employers can collaborate to deliver better, longer-lasting results.
